ARQT - Arcutis granted FDA label expansion for Zoryve psoriasis therapy
2023-10-06 09:06:09 ET
More on Arcutis
- Arcutis Biotherapeutics, Inc. (ARQT) Q2 2023 Earnings Call Transcript
- Arcutis Biotherapeutics, Inc. 2023 Q2 - Results - Earnings Call Presentation
- Arcutis: Zoryve - A Challenging Launch With Progress
- Arcutis posts late-stage win for atopic dermatitis therapy in children
- Arcutis inks licensing deal to launch psoriasis cream in Asia
For further details see:
Arcutis granted FDA label expansion for Zoryve psoriasis therapy